Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $66.67 Average Price Target from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $66.6667.

RVPH has been the subject of a number of research reports. Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 1st quarter valued at $58,000. XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals in the 2nd quarter worth $31,000. Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals in the 3rd quarter worth $37,000. State Street Corp lifted its stake in Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ:RVPH opened at $0.56 on Wednesday. The firm has a market capitalization of $7.41 million, a PE ratio of -0.14 and a beta of 0.47. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $17.20. The firm has a fifty day moving average of $0.58 and a 200 day moving average of $2.56.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, sell-side analysts forecast that Reviva Pharmaceuticals will post -2.96 EPS for the current fiscal year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.